JPWO2019024845A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019024845A5 JPWO2019024845A5 JP2020504160A JP2020504160A JPWO2019024845A5 JP WO2019024845 A5 JPWO2019024845 A5 JP WO2019024845A5 JP 2020504160 A JP2020504160 A JP 2020504160A JP 2020504160 A JP2020504160 A JP 2020504160A JP WO2019024845 A5 JPWO2019024845 A5 JP WO2019024845A5
- Authority
- JP
- Japan
- Prior art keywords
- crystalline
- solvent
- compound
- rays
- dissolving
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims 10
- 238000000634 powder X-ray diffraction Methods 0.000 claims 3
- 239000002994 raw material Substances 0.000 claims 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 2
- 239000002608 ionic liquid Substances 0.000 claims 2
- 150000002576 ketones Chemical class 0.000 claims 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 2
- 150000002825 nitriles Chemical class 0.000 claims 2
- GSGLHYXFTXGIAQ-UHFFFAOYSA-M 1,3-dimethylimidazol-1-ium;dimethyl phosphate Chemical compound COP([O-])(=O)OC.CN1C=C[N+](C)=C1 GSGLHYXFTXGIAQ-UHFFFAOYSA-M 0.000 claims 1
- GUNLDCBYXHFZDM-UHFFFAOYSA-H 1-ethyl-3-methylimidazol-3-ium;hexafluoroantimony(1-) Chemical compound F[Sb-](F)(F)(F)(F)F.CC[N+]=1C=CN(C)C=1 GUNLDCBYXHFZDM-UHFFFAOYSA-H 0.000 claims 1
- BXSDLSWVIAITRQ-UHFFFAOYSA-M 1-ethyl-3-methylimidazol-3-ium;methyl sulfate Chemical compound COS([O-])(=O)=O.CCN1C=C[N+](C)=C1 BXSDLSWVIAITRQ-UHFFFAOYSA-M 0.000 claims 1
- 206010022437 Insomnia Diseases 0.000 claims 1
- 125000003158 alcohol group Chemical group 0.000 claims 1
- 238000002425 crystallisation Methods 0.000 claims 1
- 230000005712 crystallization Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000001788 irregular Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000033764 rhythmic process Effects 0.000 claims 1
- 238000003756 stirring Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 238000010828 elution Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 2
- 230000036912 Bioavailability Effects 0.000 description 1
- 230000035514 bioavailability Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022182194A JP2023027066A (ja) | 2017-08-01 | 2022-11-15 | オレキシン受容体拮抗薬の結晶形及びその製造方法並びに用途 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710648135 | 2017-08-01 | ||
| CN201710648135.2 | 2017-08-01 | ||
| PCT/CN2018/097797 WO2019024845A1 (zh) | 2017-08-01 | 2018-07-31 | 一种食欲素受体拮抗剂的晶型及其制备方法和用途 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022182194A Division JP2023027066A (ja) | 2017-08-01 | 2022-11-15 | オレキシン受容体拮抗薬の結晶形及びその製造方法並びに用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020528913A JP2020528913A (ja) | 2020-10-01 |
| JPWO2019024845A5 true JPWO2019024845A5 (zh) | 2022-03-02 |
| JP7179049B2 JP7179049B2 (ja) | 2022-11-28 |
Family
ID=65233118
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020504160A Active JP7179049B2 (ja) | 2017-08-01 | 2018-07-31 | オレキシン受容体拮抗薬の結晶形及びその製造方法並びに用途 |
| JP2022182194A Pending JP2023027066A (ja) | 2017-08-01 | 2022-11-15 | オレキシン受容体拮抗薬の結晶形及びその製造方法並びに用途 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022182194A Pending JP2023027066A (ja) | 2017-08-01 | 2022-11-15 | オレキシン受容体拮抗薬の結晶形及びその製造方法並びに用途 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US10759779B2 (zh) |
| JP (2) | JP7179049B2 (zh) |
| CN (2) | CN115710250A (zh) |
| WO (1) | WO2019024845A1 (zh) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220194925A1 (en) * | 2019-05-15 | 2022-06-23 | Eisai R&D Management Co., Ltd. | Method and compound useful in preparation of orexin-2 receptor antagonist, and lemborexant having few impurities |
| WO2020263253A1 (en) * | 2019-06-26 | 2020-12-30 | Moline Margaret | Lemborexant for treating sleep issues |
| EP3993801A4 (en) * | 2019-09-13 | 2023-07-19 | Eisai R&D Management Co., Ltd. | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INSOMNIA |
| JP2023506025A (ja) | 2019-12-11 | 2023-02-14 | テバ チェコ インダストリーズ エス．アール．オー． | レンボレキサントの固体形態 |
| CN114901285A (zh) * | 2020-01-16 | 2022-08-12 | 卫材R&D管理有限公司 | 莱博雷生的原料药及含有其的医药组合物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6020157A (en) * | 1997-04-30 | 2000-02-01 | Smithkline Beecham Corporation | Polynucleotides encoding HFGAN72X receptor |
| US6166193A (en) * | 1997-07-25 | 2000-12-26 | Board Of Regents, University Of Texas System | Polynucleotides encoding MY1 receptor |
| PE20081229A1 (es) * | 2006-12-01 | 2008-08-28 | Merck & Co Inc | Antagonistas de receptor de orexina de diazepam sustituido |
| PE20091010A1 (es) * | 2007-10-10 | 2009-08-08 | Actelion Pharmaceuticals Ltd | Derivados de tetrahidroquinolina |
| SI2626350T1 (sl) | 2010-09-22 | 2015-09-30 | Eisai R&D Management Co., Ltd. | Spojina ciklopropana |
| RU2617696C2 (ru) | 2012-02-17 | 2017-04-26 | ЭЙСАЙ Ар ЭНД Ди МЕНЕДЖМЕНТ КО., ЛТД | Способы и соединения, которые можно использовать для синтеза антагонистов рецепторов орексина-2 |
| AU2015336463B2 (en) * | 2014-10-23 | 2020-06-18 | Eisai R&D Management Co., Ltd. | Compositions and methods for treating insomnia |
| CN104592184B (zh) * | 2014-12-15 | 2017-09-29 | 云南省药物研究所 | 灯盏乙素苷元晶型及其制备方法 |
-
2018
- 2018-07-31 CN CN202211397034.XA patent/CN115710250A/zh active Pending
- 2018-07-31 CN CN201880040538.1A patent/CN110799501B/zh active Active
- 2018-07-31 WO PCT/CN2018/097797 patent/WO2019024845A1/zh active Application Filing
- 2018-07-31 JP JP2020504160A patent/JP7179049B2/ja active Active
-
2020
- 2020-01-30 US US16/777,121 patent/US10759779B2/en active Active
-
2022
- 2022-11-15 JP JP2022182194A patent/JP2023027066A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7145931B2 (ja) | 化合物の結晶多形、その製造方法及び用途 | |
| JPH06504275A (ja) | （−）−［［４−（１，４，５，６−テトラヒドロ−４−メチル−６−オキソ−３−ピリダジニル）フェニル］ヒドラゾノ］プロパンジニトリル | |
| JP2020533396A (ja) | Ｇｓｋ１２７８８６３の結晶形及びその製造方法並びに医薬用途 | |
| JP2012519715A (ja) | アゴメラチンの新規結晶形態ｖｉ、製造方法及びその応用 | |
| JP2011516430A (ja) | ルビプロストン結晶、その製造方法および用途 | |
| JP2019504033A (ja) | 選択的なｓ１ｐ１受容体アゴニストの新規な結晶形及びその製造方法 | |
| EP1844017A1 (en) | An amorphous and three crystalline forms of rimonabant hydrochloride | |
| JP2009143954A (ja) | チアゾリジンジオン誘導体および抗糖尿病薬としてのその使用 | |
| EP0579681A1 (en) | Crystalline tiagabine hydrochloride monohydrate, its preparation and use | |
| JP2023122634A (ja) | トリエチレンテトラミン四塩酸塩、その製造方法及び組成物 | |
| JP6203170B2 (ja) | アゴメラチンの新しい結晶形ｖｉｉ、その調製方法及び使用並びにこれを含有する医薬組成物 | |
| JP7007300B2 (ja) | ダパグリフロジンの新規な結晶形並びにその製造方法および用途 | |
| CN102452951B (zh) | 阿戈美拉汀及其药物组合物 | |
| JPWO2019024845A5 (zh) | ||
| MX2013010634A (es) | Cristal mixto de agomelatina (forma-viii), sus metodos de preparacion y aplicaciones y composiciones farmaceuticas que le contienen. | |
| JP7433288B2 (ja) | イサブコナゾニウム硫酸塩を精製するための方法 | |
| GB2495458A (en) | Preparation method for and uses of carboprost tromethamine crystal | |
| JP2020505355A (ja) | Ｇｆｔ−５０５の結晶形及びその製造方法並びに用途 | |
| JP2009102356A (ja) | 新規な結晶構造を有するエリスロマイシン誘導体及びその製造方法 | |
| RU2451016C2 (ru) | Тозилатная соль транс-n-изобутил-3-фтор-3-[3-фтор-4-(пирролидин-1-илметил)фенил]циклобутанкарбоксамида | |
| JPWO2002083633A1 (ja) | トシル酸スプラタスト結晶 | |
| JP2004522780A (ja) | トルセミド・モディフィケーションｉｉを含む安定な医薬品製剤 | |
| JP2015521179A (ja) | アゴメラチン酸基複合体およびその製造方法と用途 | |
| CN105566303A (zh) | 达卡他韦新晶型及其制备方法 | |
| JP4826051B2 (ja) | スチルベン誘導体の新規結晶及びその製造方法 |